查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566884

老龄化黄斑部病变市场：按药物类型、疾病类型和分销管道划分：2024-2033 年全球机会分析和产业预测

Age Related Macular Degeneration Market By Drug Type , By Disease Type (Wet Age Related Macular Degeneration , Dry Age Related Macular Degeneration ) By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3个工作天内

价格
简介目录

老龄化黄斑部病变市场

2023年，老龄化黄斑部病变市场价值为100亿美元，预计2024年至2033年复合年增长率为5%，到2033年达到162亿美元。

老龄化黄斑部病变是一种视力障碍，会导致视网膜中央部分（称为黄斑部）劣化。它开始时视力轻微模糊，最终导致中心视力丧失。这种疾病有两类：干性（萎缩性）和湿性（新生血管性）。在干性黄斑部病变中，黄斑逐渐变薄，而在湿性黄斑部病变，视网膜下的血管异常生长。

老化人口的指数级增长和盛行率的上升是老龄化黄斑部病变市场的主要驱动力。此外，诊断技术的进步促进了疾病的早期发现和及时治疗，支持了市场开拓。最近，人工智慧和深度学习彻底改变了老龄化黄斑部病变的诊断和治疗模式。该技术有助于准确检测眼部状况并评估疾病进展的风险。

然而，当疾病处于高度晚期时，治疗方法效果有限，限制了老龄化黄斑部病变市场的成长。此外，购买治疗该疾病的基本药物（例如抗血管内皮生长因子注射液）的费用高昂，使部分患者无法接受治疗。这是市场开拓的障碍。英国科学期刊出版商 BioMed Central 发表的一篇论文称，与老龄化的黄斑部病变是导致视力丧失的主要原因之一，预计到 2040 年将影响 2.88 亿人。

按部门审查

老龄化黄斑部病变市场分为药物类型、疾病类型、通路和区域。依药物类型分为阿柏西普、雷珠单抗等。依疾病类型分为湿性老龄化黄斑部病变（AMD）和干性老龄化黄斑部病变（AMD）。依销售管道分为医院药局、零售药局、网路药局。从区域来看，分析包括北美、欧洲、亚太地区和拉丁美洲地区。

主要发现

从药物类型来看，阿柏西普在老龄化黄斑部病变病变市场中占据主导地位。

依疾病类型划分，湿性老龄化黄斑部病变（AMD）细分市场占有重要份额。

从销售管道来看，医院药局板块处于市场领先地位。

从地区来看，北美市场呈现强劲成长动能。

该报告可以定制。

  • 监管指引
  • 新增根据客户兴趣客製化的公司简介
  • 公司简介的扩充列表
  • 历史市场资料

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 主要投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

老龄化黄斑部病变市场：依药物类型

  • 市场概况
  • 阿柏西普
  • 雷珠单抗
  • 其他的

老龄化黄斑部病变市场：依疾病类型

  • 市场概况
  • 湿性老龄化黄斑部病变（AMD）
  • 干性老龄化黄斑部病变（AMD）

第六章老龄化黄斑部病变市场：按分销管道

  • 市场概况
  • 医院药房
  • 零售药房
  • 网路药房

第七章市场概述老龄化黄斑部病变市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国老龄化黄斑部病变市场
    • 加拿大老龄化黄斑部病变市场
    • 墨西哥老龄化黄斑部病变市场
  • 欧洲
    • 主要市场趋势和机会
    • 法国老龄化黄斑部病变市场
    • 德国老龄化黄斑部病变市场
    • 义大利老龄化黄斑部病变市场
    • 西班牙老龄化黄斑部病变市场
    • 英国老龄化黄斑部病变市场
    • 其他欧洲国家老龄化黄斑部病变市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国老龄化黄斑部病变市场
    • 日本老龄化黄斑部病变市场
    • 印度老龄化黄斑部病变市场
    • 韩国老龄化黄斑部病变市场
    • 澳洲老龄化黄斑部病变市场
    • 其他亚太地区老龄化黄斑部病变市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西老龄化黄斑部病变市场
    • 南非老龄化黄斑部病变市场
    • 沙乌地老龄化黄斑部病变市场
    • 其他拉丁美洲/中东/非洲老龄化黄斑部病变市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Biogen
  • Bayer AG
  • Coherus Biosciences Inc
  • Sanofi
  • Apellis Pharmaceuticals
  • Bausch Health Companies Inc.
  • Ionis Pharmaceuticals, Inc
简介目录
Product Code: A201849

Age Related Macular Degeneration Market

The age related macular degeneration market was valued at $10.0 billion in 2023 and is projected to reach $16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Age related macular degeneration is a visual impairment in which the central portion of the retina, known as macula, deteriorates. Beginning with slight blurred vision, the disease eventually leads to loss of central eyesight. There are two categories of the disease: dry (atrophic) and wet (neovascular). Gradual thinning of the macula occurs in dry macular degeneration, whereas wet macular degeneration happens due to abnormal growth of blood vessels under the retina.

Exponential increase in the aging population and rise in prevalence of the disease are the key drivers of the age related macular degeneration market. In addition, advancements in diagnostic techniques are leading to early detection and timely treatment of the disease, thereby augmenting the market development. In recent times, AI and deep learning are revolutionizing the landscape of age related macular degeneration diagnosis and treatment. The technology helps in precise detection of the eye condition and assesses the risk pertaining to the progression of the disease to advanced stages.

However, in case of disease advancement to high stages, treatment procedures exhibit limited to no efficacy, thereby restraining the growth of the age related macular degeneration market. Moreover, the high expense of purchasing medications essential for curing the disease, such as anti-vascular endothelial growth factor injections, constraints several patients from undergoing the treatment. This hampers the development of the market. According to an article published by the UK-based scientific journals publisher-BioMed Central- age related macular degeneration is one of the leading causes of vision loss and by 2040, the disease is anticipated to impact 288 million individuals.

Segment Review

The age related macular degeneration market is segmented into drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into aflibercept, ranibizumab, and others. Depending on disease type, it is bifurcated into wet age related macular degeneration (AMD) and dry age related macular degeneration (AMD). As per distribution channel, it is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug type, the aflibercept segment dominates the age related macular degeneration market.

Depending on disease type, the wet age-related macular degeneration (AMD) segment acquires a significant share of the market.

As per distribution channel, the hospital pharmacy segment leads in the market.

Region wise, the market exhibits robust growth in North America.

Competition Analysis

The leading players operating in the global age related macular degeneration market include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Biogen, Bayer AG, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals, Bausch Health Companies Inc., and Ionis Pharmaceuticals, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Drug Type

  • Aflibercept
  • Ranibizumab
  • Others

By Disease Type

  • Wet Age Related Macular Degeneration (AMD)
  • Dry Age Related Macular Degeneration (AMD)

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Regeneron Pharmaceuticals Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Bayer AG
    • Coherus Biosciences Inc
    • Sanofi
    • Apellis Pharmaceuticals
    • Bausch Health Companies Inc.
    • Ionis Pharmaceuticals, Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Type
  • 4.2. Aflibercept
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Ranibizumab
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Disease Type
  • 5.2. Wet Age Related Macular Degeneration (AMD)
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Dry Age Related Macular Degeneration (AMD)
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacy
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Retail Pharmacy
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacy
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: AGE RELATED MACULAR DEGENERATION MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Drug Type
    • 7.2.3. Market Size and Forecast, By Disease Type
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Age Related Macular Degeneration Market
      • 7.2.6.1. Market Size and Forecast, By Drug Type
      • 7.2.6.2. Market Size and Forecast, By Disease Type
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Age Related Macular Degeneration Market
      • 7.2.7.1. Market Size and Forecast, By Drug Type
      • 7.2.7.2. Market Size and Forecast, By Disease Type
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Age Related Macular Degeneration Market
      • 7.2.8.1. Market Size and Forecast, By Drug Type
      • 7.2.8.2. Market Size and Forecast, By Disease Type
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Drug Type
    • 7.3.3. Market Size and Forecast, By Disease Type
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Age Related Macular Degeneration Market
      • 7.3.6.1. Market Size and Forecast, By Drug Type
      • 7.3.6.2. Market Size and Forecast, By Disease Type
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Age Related Macular Degeneration Market
      • 7.3.7.1. Market Size and Forecast, By Drug Type
      • 7.3.7.2. Market Size and Forecast, By Disease Type
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Age Related Macular Degeneration Market
      • 7.3.8.1. Market Size and Forecast, By Drug Type
      • 7.3.8.2. Market Size and Forecast, By Disease Type
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Age Related Macular Degeneration Market
      • 7.3.9.1. Market Size and Forecast, By Drug Type
      • 7.3.9.2. Market Size and Forecast, By Disease Type
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Age Related Macular Degeneration Market
      • 7.3.10.1. Market Size and Forecast, By Drug Type
      • 7.3.10.2. Market Size and Forecast, By Disease Type
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Age Related Macular Degeneration Market
      • 7.3.11.1. Market Size and Forecast, By Drug Type
      • 7.3.11.2. Market Size and Forecast, By Disease Type
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Drug Type
    • 7.4.3. Market Size and Forecast, By Disease Type
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Age Related Macular Degeneration Market
      • 7.4.6.1. Market Size and Forecast, By Drug Type
      • 7.4.6.2. Market Size and Forecast, By Disease Type
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Age Related Macular Degeneration Market
      • 7.4.7.1. Market Size and Forecast, By Drug Type
      • 7.4.7.2. Market Size and Forecast, By Disease Type
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Age Related Macular Degeneration Market
      • 7.4.8.1. Market Size and Forecast, By Drug Type
      • 7.4.8.2. Market Size and Forecast, By Disease Type
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Age Related Macular Degeneration Market
      • 7.4.9.1. Market Size and Forecast, By Drug Type
      • 7.4.9.2. Market Size and Forecast, By Disease Type
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Age Related Macular Degeneration Market
      • 7.4.10.1. Market Size and Forecast, By Drug Type
      • 7.4.10.2. Market Size and Forecast, By Disease Type
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Age Related Macular Degeneration Market
      • 7.4.11.1. Market Size and Forecast, By Drug Type
      • 7.4.11.2. Market Size and Forecast, By Disease Type
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Drug Type
    • 7.5.3. Market Size and Forecast, By Disease Type
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Age Related Macular Degeneration Market
      • 7.5.6.1. Market Size and Forecast, By Drug Type
      • 7.5.6.2. Market Size and Forecast, By Disease Type
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Age Related Macular Degeneration Market
      • 7.5.7.1. Market Size and Forecast, By Drug Type
      • 7.5.7.2. Market Size and Forecast, By Disease Type
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Age Related Macular Degeneration Market
      • 7.5.8.1. Market Size and Forecast, By Drug Type
      • 7.5.8.2. Market Size and Forecast, By Disease Type
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Age Related Macular Degeneration Market
      • 7.5.9.1. Market Size and Forecast, By Drug Type
      • 7.5.9.2. Market Size and Forecast, By Disease Type
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Regeneron Pharmaceuticals Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. F. Hoffmann-La Roche Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Biogen
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Bayer AG
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Coherus Biosciences Inc
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Sanofi
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Apellis Pharmaceuticals
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Bausch Health Companies Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Ionis Pharmaceuticals, Inc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments